Cargando…

Temozolomide and Bevacizumab Induction before Chemoradiotherapy in Patients with Bulky Glioblastoma and/or with Severe Neurological Impairment

Background.New approaches are needed for patients newly diagnosed with bulky glioblastoma (GB) and/or with severe neurological impairment that cannot benefit from first line temozolomide (TMZ)-based chemoradiotherapy. Bevacizumab (BEV), an antiangiogenic anti-VEGF-R monoclonal antibody, has a rapid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Darmon, Ilan, Morisse, Mony Chenda, Coutte, Alexandre, Blonski, Marie, Le Rhun, Emilie, Taillandier, Luc, Roufai, Diana Bello, Desenclos, Christine, Trudel, Stéphanie, Faivre, Jean-Christophe, Blanchard, Nicolas, Chauffert, Bruno, Boone, Mathieu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479247/ https://www.ncbi.nlm.nih.gov/pubmed/28638456 http://dx.doi.org/10.7150/jca.18339

Ejemplares similares

Upfront Bevacizumab and Temozolomide or Fotemustine before Radiotherapy for Patients with Glioblastoma and Severe Neurological Impairment at Diagnosis
por: Bihan, Celina, et al.
Publicado: (2012)

Combining genomic analyses with tumour-derived slice cultures for the characterization of an EGFR-activating kinase mutation in a case of glioblastoma
por: Loriguet, Lea, et al.
Publicado: (2018)

Expression Analysis of α5 Integrin Subunit Reveals Its Upregulation as a Negative Prognostic Biomarker for Glioblastoma
por: Etienne-Selloum, Nelly, et al.
Publicado: (2021)

Thrombotic Microangiopathy Revealing Bone Metastases from an Ethmoid Sinus Carcinoma
por: Morisse, Mony Chenda, et al.
Publicado: (2016)

Intra-Arterial Delivery of Idarubicin in Two Patients with Glioblastoma
por: Chehimi, Mohamad, et al.
Publicado: (2016)

ERK1/2 signaling regulates the immune microenvironment and macrophage recruitment in glioblastoma
por: Lailler, Claire, et al.
Publicado: (2019)

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)
por: Reyes‐Botero, Germán, et al.
Publicado: (2018)

IAP inhibitor plus chemoradiotherapy for the treatment of bulky anal canal carcinoma
por: De Felice, Francesca, et al.
Publicado: (2023)

Adaptation to DNA damage checkpoint in senescent telomerase-negative cells promotes genome instability
por: Coutelier, Héloïse, et al.
Publicado: (2018)

Neoadjuvant chemoradiotherapy for locally advanced gastric cancer with bulky lymph node metastasis: Five case reports
por: Nomura, Eiji, et al.
Publicado: (2020)

Concurrent or Sequential Chemoradiotherapy after 3-4 Cycles Induction Chemotherapy for LS-SCLC with Bulky Tumor
por: Zhao, Jingjing, et al.
Publicado: (2020)

Complete Radiologic Response in an Anaplastic Oligodendroglioma Treated with Temozolomide and Bevacizumab
por: Katz, Artur, et al.
Publicado: (2009)

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
por: Lou, Emil, et al.
Publicado: (2013)

Alterations of the tumor microenvironment in glioblastoma following radiation and temozolomide with or without bevacizumab
por: Tamura, Ryota, et al.
Publicado: (2020)

ITGA5 Predicts Dual-Drug Resistance to Temozolomide and Bevacizumab in Glioma
por: Shi, Ying, et al.
Publicado: (2021)

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
por: Ohno, Makoto, et al.
Publicado: (2019)

Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea
por: Kim, Byung Sup, et al.
Publicado: (2017)

Recurrence patterns in patients with high-grade glioma following temozolomide-based chemoradiotherapy
por: Zhou, Xiaofeng, et al.
Publicado: (2016)

Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy
por: Roh, Tae Hoon, et al.
Publicado: (2020)

Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme
por: Shields, Lisa BE, et al.
Publicado: (2013)

Cost-effectiveness analysis of the addition of bevacizumab to temozolomide therapy for the treatment of unresected glioblastoma
por: Chen, Zhaoyan, et al.
Publicado: (2020)

Can a bulky glycocalyx promote catch bonding in early integrin adhesion? Perhaps a bit
por: Blanchard, Aaron
Publicado: (2023)

Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
por: Koumarianou, Anna, et al.
Publicado: (2012)

Efficacy of temozolomide and bevacizumab for the treatment of leptomeningeal dissemination of recurrent glioblastoma: A case report
por: OKITA, YOSHIKO, et al.
Publicado: (2015)

Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature
por: Jeck, Jennifer, et al.
Publicado: (2018)

Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice
por: Carter, Tonia C., et al.
Publicado: (2018)

Surgery, Octreotide, Temozolomide, Bevacizumab, Radiotherapy, and Pegvisomant Treatment of an AIP Mutation‒Positive Child
por: Dutta, Pinaki, et al.
Publicado: (2019)

Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma
por: Adilijiang, Alimu, et al.
Publicado: (2019)

Bevacizumab-induced tracheoesophageal fistula in a patient suffering from lung cancer with bulky subcarinal lymph node: a case report
por: Nishie, Kenichi, et al.
Publicado: (2018)

The Definition and Delineation of the Target Area of Radiotherapy Based on the Recurrence Pattern of Glioblastoma After Temozolomide Chemoradiotherapy
por: Zheng, Lin, et al.
Publicado: (2021)

Bevacizumab/temozolomide/unspecified steroids: Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis: case report
Publicado: (2020)

Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts
por: Nishri, Yossi, et al.
Publicado: (2022)

Comparison of Oncologic Outcomes between Radical Hysterectomy and Primary Concurrent Chemoradiotherapy in Women with Bulky IB and IIA Cervical Cancer under Risk Stratification
por: Chen, Chung-Shih, et al.
Publicado: (2023)

Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma
por: Piperno-Neumann, Sophie, et al.
Publicado: (2016)

Aberrant glioblastoma neovascularization patterns and their correlation with DCE-MRI-derived parameters following temozolomide and bevacizumab treatment
por: Xue, Wei, et al.
Publicado: (2017)

DIPG-12. OUTCOMES IN PEDIATRIC MALIGNANT CENTRAL NERVOUS SYSTEM TUMORS UTILIZING TEMOZOLOMIDE, BEVACIZUMAB, AND IRINOTECAN
por: Reel, Sarah, et al.
Publicado: (2023)

Dynamic (18)F-FDopa PET Imaging for Newly Diagnosed Gliomas: Is a Semiquantitative Model Sufficient?
por: Zaragori, Timothée, et al.
Publicado: (2021)

Oxidation of Isoeugenol by Salen Complexes with Bulky Substituents
por: Salanti, Anika, et al.
Publicado: (2010)

Permeability of the fish intestinal membrane to bulky chemicals
por: Miyata, Chiyoko, et al.
Publicado: (2022)

Relevance of two manual tumour volume estimation methods for diffuse low-grade gliomas
por: Ben Abdallah, Meriem, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5ok233186oti6pfuupa9a29kor